Two Pore Guys closed a $24.5 million Series A round, which will boost the manufacturing of the company’s handheld testing system.
Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.
It’s a critical tradeoff for life. Our bodies use sugar and fat from the food we consume to produce energy in our cells’ mitochondria, the internal powerhouses…
It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…
Private equity giant KKR is reportedly in “advanced” discussions to acquire a stake in New Delhi-based SRL Diagnostics, a deal potentially worth $775 million.
The beta blocker carvedilol may see new life as a sunscreen, thanks to researchers who found that the drug may prevent sun damage that leads to skin cancer.
HTG Molecular Diagnostics is teaming up with Spain’s Instituto Valenciano de Oncología to develop a score to predict breast cancer recurrence.
European pharma leaders have drafted an open letter calling for strenuous efforts to avoid disruption at the EMA post-Brexit.
Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff.
French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in…
Argenx has filed to raise up to $75 million in a Nasdaq IPO to take lead candidate ARGX-113 to the cusp of a pivotal trial.